Category: Endologix Inc.
Calhoun Vision replaces Verne Sharma in the corner office with former Bausch & Lomb executive Rick Heinick.
Endologix launches a clinical trial after landing FDA Investigational Device Exemption for the Nellix endovascular aneurysm sealing system.
Endologix (NSDQ:ELGX) said it won FDA Investigational Device Exemption for its Nellix endovascular aneurysm sealing system, paving the way for a U.S. clinical trial.
Endologix is seeking to raise $75 million through sales of convertible notes with 2018 due dates.
Endologix (NSDQ:ELGX) announced this week that the company is offering $75 million in convertible notes.
Ali Haghighi-Mood, the former president & CEO of Cambridge Heart, and chairman Roderick de Greef both resign for unnamed reasons.
Cambridge Heart (NSDQ:CAMH) said chairman and interim president Roderick de Greef and former president & CEO Ali Haghighi-Mood have both resigned from the medical device company.
Third-quarter sales surge for Endologix, but losses widen as it raises its earnings outlook and narrows its sales guidance for the rest of the year.
Endologix (NSDQ:ELGX) posted sales growth of nearly 25% during the 3rd quarter, but losses widened by nearly 58%.
Irvine, Calif.-based Endologix posted losses of $9.5 million, or 14¢ per share, on sales of $33.3 million for the 3 months ended Sept. 30. That's a profit slide of 57.9% on sales growth of 24.6% compared with the same period last year.
Endologix beats the Street as the company's bottom line swings to the black during the 2nd quarter.
Endologix (NSDQ:ELGX) beat Wall Street estimates by 2 cents and cut losses in the 2nd quarter, sending share prices up 5.3% to almost $16 in the days following the earnings results.
Lifesciences investment firm Iguana Healthcare Partners raises $53.5 million in pooled interests.
New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests.
The funding, raised among 20 unnamed investors, will support Iguana's interests in pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and healthcare information technology.